Mucosal-associated invariant T cell responses differ by sex in COVID-19

C Yu, S Littleton, NS Giroux, R Mathew, S Ding… - Med, 2021 - cell.com
C Yu, S Littleton, NS Giroux, R Mathew, S Ding, J Kalnitsky, Y Yang, E Petzold, HA Chung
Med, 2021cell.com
Background Sexual dimorphisms in immune responses contribute to coronavirus disease
2019 (COVID-19) outcomes, but the mechanisms governing this disparity remain
incompletely understood. Methods We carried out sex-balanced sampling of peripheral
blood mononuclear cells from hospitalized and non-hospitalized individuals with confirmed
COVID-19, uninfected close contacts, and healthy control individuals for 36-color flow
cytometry and single-cell RNA sequencing. Findings Our results revealed a pronounced …
Background
Sexual dimorphisms in immune responses contribute to coronavirus disease 2019 (COVID-19) outcomes, but the mechanisms governing this disparity remain incompletely understood.
Methods
We carried out sex-balanced sampling of peripheral blood mononuclear cells from hospitalized and non-hospitalized individuals with confirmed COVID-19, uninfected close contacts, and healthy control individuals for 36-color flow cytometry and single-cell RNA sequencing.
Findings
Our results revealed a pronounced reduction of circulating mucosal-associated invariant T (MAIT) cells in infected females. Integration of published COVID-19 airway tissue datasets suggests that this reduction represented a major wave of MAIT cell extravasation during early infection in females. Moreover, MAIT cells from females possessed an immunologically active gene signature, whereas cells from males were pro-apoptotic.
Conclusions
Our findings uncover a female-specific protective MAIT cell profile, potentially shedding light on reduced COVID-19 susceptibility in females.
Funding
This work was supported by NIH/NIAID (U01AI066569 and UM1AI104681), the Defense Advanced Projects Agency (DARPA; N66001-09-C-2082 and HR0011-17-2-0069), the Veterans Affairs Health System, and Virology Quality Assurance (VQA; 75N93019C00015). The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health. COVID-19 samples were processed under Biosafety level 2 (BSL-2) with aerosol management enhancement or BSL-3 in the Duke Regional Biocontainment Laboratory, which received partial support for construction from NIH/NIAID (UC6AI058607).
cell.com